The Effect of COX-2 Inhibitor on the Growth and Metastasis of Gastric Cancer Xenograft.
- Author:
Joung Sik OH
1
;
Woo Jung SIM
;
Sung Jae CHA
;
Kyong Choun CHI
;
Sung Jun PARK
;
Hyun Muck LIM
;
Sung Il PARK
;
Tae Jin LEE
;
Eon Sub PARK
Author Information
1. Department of General Surgery, College of Medicine, Chung-Ang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
COX-2;
Gastric cancer;
Tumor growth;
Metastasis
- MeSH:
Administration, Oral;
Animals;
Apoptosis;
Cadherins;
Carcinogenesis;
Cell Line;
Cyclooxygenase 2;
Cyclooxygenase 2 Inhibitors;
Heterografts*;
Humans;
Metalloproteases;
Mice;
Mice, Nude;
Neoplasm Metastasis*;
Prognosis;
Stomach Neoplasms*;
Tissue Inhibitor of Metalloproteinase-2;
Tumor Burden
- From:Journal of the Korean Surgical Society
2002;62(2):95-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Tumor invasion and metastasis are known to be extremely important factors in the prognosis of cancer patients. Although recent studies have demonstrated that cyclooxygenase-2 (COX-2) is overexpressed in various cancers including gastric cancer, the mechanisms underlying the contribution of COX-2 to tumorigenesis and tumor promotion remain unclear. METHODS: In order to determine the role of COX-2 in tumor growth and metastasis, we investigated COX-2 expression, apoptosis and the expression of E-cadherin, CD44v6, MMP-2 and TIMP-2 in gastric cancer xenografts treated with meloxicam (a selective COX-2 inhibitor). RESULTS: Cells from the MKN45 gastric cancer cell line that overexpress COX-2 were inoculated subcutaneously into athymic mice. Oral administration with meloxicam reduced the tumor volume (P<0.01), induced apoptosis of cancer cells (P<0.01), suppressed the proliferation rates (P<0.01), increased the expression of E-cadhrin (P<0.05) and reduced the expression of MMP-2 and TIMP-2. CONCLUSION: The above data showed that COX-2 inhibitors can inhibit tumor growth and suppress metastatic potential by expression of adhesion molecules and suppression of metalloproteinases, suggesting that this inhibitor can be used as an additive anti-cancer drug in cases of stomach cancer with radical resection, although further evaluation is required.
